Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q2

3151.TEDINET S100S8PO
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥294.2bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥581.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥290.2bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥2.9bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥1.5bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥3.5bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥6.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥3.5bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥2.4bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥2.3bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥1.5bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥321.7bnat 2023-09-30Cons.Assets
Total assets¥297.3bnat 2023-03-31Cons.Assets
Total assets¥316.4bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥219.0bnat 2023-09-30Cons.Liabilities
Total liabilities¥197.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥102.8bnat 2023-09-30Cons.Net assets
Net assets / equity¥100.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥103.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥30.5bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥19.0bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥26.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥15.1bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥23.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥23.2bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥16.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥3.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥4.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥45.782023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.032023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.692022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥27.422022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.42022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio31.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.4%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥3.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥108m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥6.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥6.6bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥39m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2023-04-01 → 2023-09-30¥282.5bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2023-04-01 → 2023-09-30¥277.2bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2023-04-01 → 2023-09-30¥2.6bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥9.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥6m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥114m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.6bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.6bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥183m
—segment totalrevenue2023-04-01 → 2023-09-30¥297.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥292.2bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥5.3bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥300.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥294.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥6.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥2.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥3.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥146m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥6.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥6.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥58m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2022-04-01 → 2022-09-30¥279.0bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2022-04-01 → 2022-09-30¥273.8bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2022-04-01 → 2022-09-30¥1.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥32m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥182m
—segment totalrevenue2022-04-01 → 2022-09-30¥293.3bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥288.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥1.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥296.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥290.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 545
ItemContextValueUnit
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E22440-000MedicalProductsWholesaleReportableSegmentsMember277201000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E22440-000PharmacyBusinessReportableSegmentMember9386000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember5589000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember292178000000JPY
Revenues from external customersCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember2035000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember294213000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration294213000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E22440-000MedicalProductsWholesaleReportableSegmentsMember5276000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E22440-000PharmacyBusinessReportableSegmentMember6000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember0JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember5283000000JPY
Transactions with other segmentsCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember1300000000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember6583000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-6583000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E22440-000MedicalProductsWholesaleReportableSegmentsMember282478000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E22440-000PharmacyBusinessReportableSegmentMember9392000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember5589000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember297461000000JPY
Net salesCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember3335000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember300797000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-6583000000JPY
Net salesCurrentYTDDuration294213000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E22440-000MedicalProductsWholesaleReportableSegmentsMember2640000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E22440-000PharmacyBusinessReportableSegmentMember114000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember183000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember2938000000JPY
Operating incomeCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-108000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember2829000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember39000000JPY
Operating incomeCurrentYTDDuration2868000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-11-13
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第15期第２四半期(自 2023年７月１日 至 2023年９月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社バイタルケーエスケー・ホールディングス
Company name in english cover pageFilingDateInstantVITAL KSK HOLDINGS, INC.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　村　井　泰　介
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都世田谷区弦巻一丁目１番12号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)(03)5787－8550(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)執行役員経営企画部長　　高　橋　喜　春
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都世田谷区弦巻一丁目１番12号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)(03)5787－8550(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)執行役員経営企画部長　　高　橋　喜　春
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE22440
Fund codeFilingDateInstant－
Security codeFilingDateInstant31510

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass